Department of Pathology, National University Health System, Singapore 119074, Singapore.
Hum Pathol. 2010 Apr;41(4):552-9. doi: 10.1016/j.humpath.2009.09.008. Epub 2009 Dec 11.
Four cases of large cell calcifying Sertoli cell tumor, 3 benign and 1 malignant, with no clinical signs of Carney complex or Peutz-Jeghers syndrome are reported with results of histologic, immunohistochemical, ultrastructural, and comparative genomic hybridization studies. Analysis of PRKAR1A gene was performed on 2 cases. The age range of the patients was 19 to 54 years. The patient with a malignant large cell calcifying Sertoli cell tumor died of disease 4 years after surgery. Patients with benign tumors have had an uneventful follow-up for 1 and 3 years. All tumors were well circumscribed, unencapsulated, and composed of solid sheets, irregular cords, tubular structures, and nests in a fibrous and/or myxoid stroma with cellular atypia in the malignant case. All tumors showed diffuse immunoreactivity for inhibin, vimentin, calretinin, and S100 protein. Focal positivity for cytokeratin (AE1/AE3) was noticed in 1 case. Tumors were negative for CAM 5.2, Mic-2, Melan-A laminin, placental alkaline phosphatase, and alpha-fetoprotein. The proliferation index was 5% and 10% for 2 of the benign tumors and 30% for the malignant tumor. Comparative genomic hybridization was performed in 2 cases. There was no evidence of any major chromosomal changes. In one case, no PRKAR1A gene mutation was found. In the other case, a heterozygous shift mutation c.65_84dup was found, despite the absence of other clinical signs of Carney complex or Peutz-Jeghers syndrome. Although the combination of large cell calcifying Sertoli cell tumor and PRKAR1A mutation fulfills the criteria for establishing a diagnosis of Carney complex, the clinical relevance of finding a PRKAR1A gene mutation in a patient without any clinical signs of Carney complex or Peutz-Jeghers syndrome remains to be established.
报告了 4 例大细胞钙化性支持细胞瘤,3 例为良性,1 例为恶性,均无卡尼复合征或皮杰氏综合征的临床征象,并进行了组织学、免疫组织化学、超微结构和比较基因组杂交研究。对 2 例病例进行了 PRKAR1A 基因分析。患者年龄为 19-54 岁。患有恶性大细胞钙化性支持细胞瘤的患者在手术后 4 年内死于疾病。良性肿瘤患者的随访时间分别为 1 年和 3 年,均无异常。所有肿瘤均边界清楚,无包膜,由实性片层、不规则索状、管状结构和巢状结构组成,在恶性病例中可见细胞异型性,伴有纤维和/或黏液样基质。所有肿瘤均弥漫性表达抑制素、波形蛋白、钙视网膜蛋白和 S100 蛋白。1 例病例中发现细胞角蛋白(AE1/AE3)局灶性阳性。肿瘤对 CAM5.2、Mic-2、Melan-A 层粘连蛋白、胎盘碱性磷酸酶和α-胎蛋白均为阴性。2 例良性肿瘤的增殖指数为 5%和 10%,而恶性肿瘤为 30%。对 2 例病例进行了比较基因组杂交。没有发现任何主要染色体变化。在 1 例病例中未发现 PRKAR1A 基因突变。在另 1 例病例中,发现了杂合性移码突变 c.65_84dup,尽管没有卡尼复合征或皮杰氏综合征的其他临床征象。尽管大细胞钙化性支持细胞瘤与 PRKAR1A 突变的组合符合建立卡尼复合征诊断的标准,但在无卡尼复合征或皮杰氏综合征临床征象的患者中发现 PRKAR1A 基因突变的临床意义仍有待确定。